Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H29N9O9S2 |
Molecular Weight | 627.651 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12SCC(CSC3=NN=NN3C)=C(N1C(=O)[C@]2(NC(=O)[C@H](NC(=O)N4CCN(CC)C(=O)C4=O)[C@H](C)O)OC)C(O)=O
InChI
InChIKey=SMSRCGPDNDCXFR-CYWZMYCQSA-N
InChI=1S/C22H29N9O9S2/c1-5-29-6-7-30(16(35)15(29)34)20(39)23-12(10(2)32)14(33)24-22(40-4)18(38)31-13(17(36)37)11(8-41-19(22)31)9-42-21-25-26-27-28(21)3/h10,12,19,32H,5-9H2,1-4H3,(H,23,39)(H,24,33)(H,36,37)/t10-,12+,19+,22-/m0/s1
DescriptionCurator's Comment: Description was created based on several sources, including https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C81029 and http://www.ncbi.nlm.nih.gov/pubmed/6348335
Curator's Comment: Description was created based on several sources, including https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=NCI_Thesaurus&code=C81029 and http://www.ncbi.nlm.nih.gov/pubmed/6348335
Cefbuperazone (cefalosporin antibiotic) is marketed under the brand name Keiperazon by Kaken, and Tomiproan by Toyama, Japan. It is powder for injection 0.5 and 1 g/ampoule. It is indicated to treat infections with susceptible microorganisms. It has been proposed especially against Pseudomonas infections. Cefbuperazone binds to and inactivates penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Bacteroides fragilis growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/3874597 |
|||
Target ID: Escherichia coli growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/18765691 |
|||
Target ID: map00550 |
|||
Target ID: Staphylococcus aureus growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/6348338 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Tomiporan Approved UseIndications: infections with susceptible microorganisms. Launch Date1985 |
|||
Curative | Tomiporan Approved UseIndications: infections with susceptible microorganisms. Launch Date1985 |
PubMed
Title | Date | PubMed |
---|---|---|
In vitro activity of cefbuperazone compared with that of other new beta-lactam agents against anaerobic gram-negative bacilli and contribution of beta-lactamase to resistance. | 1985 May |
|
In vivo bacterial regrowth-inhibition effect of cefbuperazone and amikacin in puerperal uterine cavity. | 1995 Nov |
|
Pharmacokinetic profile of cefbuperazone in healthy Chinese volunteers after single and multiple drip intravenous infusion by HPLC-MS/MS. | 2016 Sep 10 |
Sample Use Guides
intravenous injection at a daily dose of 2g (1g - 2 times)
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/3874597
Cefbuperazone inhibited Bacteroides fragilis growth with MIC50 16 ug/ml
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C357
Created by
admin on Fri Dec 15 15:25:28 GMT 2023 , Edited by admin on Fri Dec 15 15:25:28 GMT 2023
|
||
|
WHO-ATC |
J01DC13
Created by
admin on Fri Dec 15 15:25:28 GMT 2023 , Edited by admin on Fri Dec 15 15:25:28 GMT 2023
|
||
|
WHO-VATC |
QJ01DC13
Created by
admin on Fri Dec 15 15:25:28 GMT 2023 , Edited by admin on Fri Dec 15 15:25:28 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C035978
Created by
admin on Fri Dec 15 15:25:28 GMT 2023 , Edited by admin on Fri Dec 15 15:25:28 GMT 2023
|
PRIMARY | |||
|
5216
Created by
admin on Fri Dec 15 15:25:28 GMT 2023 , Edited by admin on Fri Dec 15 15:25:28 GMT 2023
|
PRIMARY | |||
|
CHEMBL1908372
Created by
admin on Fri Dec 15 15:25:28 GMT 2023 , Edited by admin on Fri Dec 15 15:25:28 GMT 2023
|
PRIMARY | |||
|
76610-84-9
Created by
admin on Fri Dec 15 15:25:28 GMT 2023 , Edited by admin on Fri Dec 15 15:25:28 GMT 2023
|
PRIMARY | |||
|
CEFBUPERAZONE
Created by
admin on Fri Dec 15 15:25:28 GMT 2023 , Edited by admin on Fri Dec 15 15:25:28 GMT 2023
|
PRIMARY | |||
|
135856
Created by
admin on Fri Dec 15 15:25:28 GMT 2023 , Edited by admin on Fri Dec 15 15:25:28 GMT 2023
|
PRIMARY | |||
|
m3189
Created by
admin on Fri Dec 15 15:25:28 GMT 2023 , Edited by admin on Fri Dec 15 15:25:28 GMT 2023
|
PRIMARY | Merck Index | ||
|
C81029
Created by
admin on Fri Dec 15 15:25:28 GMT 2023 , Edited by admin on Fri Dec 15 15:25:28 GMT 2023
|
PRIMARY | |||
|
3072
Created by
admin on Fri Dec 15 15:25:28 GMT 2023 , Edited by admin on Fri Dec 15 15:25:28 GMT 2023
|
PRIMARY | |||
|
DB13638
Created by
admin on Fri Dec 15 15:25:28 GMT 2023 , Edited by admin on Fri Dec 15 15:25:28 GMT 2023
|
PRIMARY | |||
|
127527
Created by
admin on Fri Dec 15 15:25:28 GMT 2023 , Edited by admin on Fri Dec 15 15:25:28 GMT 2023
|
PRIMARY | |||
|
T0785J3X40
Created by
admin on Fri Dec 15 15:25:28 GMT 2023 , Edited by admin on Fri Dec 15 15:25:28 GMT 2023
|
PRIMARY | |||
|
DTXSID701024595
Created by
admin on Fri Dec 15 15:25:28 GMT 2023 , Edited by admin on Fri Dec 15 15:25:28 GMT 2023
|
PRIMARY | |||
|
100000081813
Created by
admin on Fri Dec 15 15:25:28 GMT 2023 , Edited by admin on Fri Dec 15 15:25:28 GMT 2023
|
PRIMARY | |||
|
SUB07380MIG
Created by
admin on Fri Dec 15 15:25:28 GMT 2023 , Edited by admin on Fri Dec 15 15:25:28 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)